Investigational NMDA receptor modulators for depression
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: With regards to depression, the role of N-methyl-D-aspartate receptor (NMDA) was pursued many years ago, mainly in the form of preclinical studies. Since then, there have been several clinical data in the literature indicating the efficacy of NMDA receptor antagonists of either stand-alone or as an adjunct therapy in depression and depression-related diseases. AREAS COVERED: The present review focuses on clinical data of well-known and recently discovered NMDA receptor antagonists/modulators and their mechanisms of action. EXPERT OPINION: Several NMDA receptor modulators have been tested in both human and animal studies to examine their potential antidepressant activity. Most of the compounds that exhibited beneficial properties in the animal tests and models of depression either have never been tested or did not show efficacy in humans. For some of them, such as ketamine, where a consistently reproducible antidepressant effect was found, clinical use is limited by a variety of adverse effects. However, ketamine has become a standard tool for identifying the biological factors associated with rapid antidepressant action and, as such, is a novel target for the development of new therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“Differential molecular architecture of the NMDA receptors implies distinct functional properties and regulation [16-19].”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 13×
“[50] examined themolecular effects 2 h after ketamine administration but Autry et al.”
BackgroundInfluentialNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“The next possible mechanism responsible for the rapid antidepressant action of ketamine raised recently is the rapid synthesis of the brain-derived neurotrophic factor (BDNF) as an effect due to the blockade of the NMDA receptor at rest and reduced activity of eEF2K (eukaryotic elongation factor 2 kinase) [44], which…”
BackgroundResultInfluentialMolecular cloning and characterization of the rat NMDA receptor
Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1991) · Nature · doi:10.1038/354031a0 · Cited by 1,771 · cited 1×
“Differential molecular architecture of the NMDA receptors implies distinct functional properties and regulation [16-19].”
BackgroundmTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 11×
“Drugs (2012) 21(1) together with low and ineffective doses of magnesium induces a significant reduction in immobility time in FST [67].”
BackgroundInfluentialDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“Rapid antidepressant efficacy of a ketamine infusion was also found in resistant depressive patients with a confirmed family history of alcohol dependence [36]; in patients with suicidal ideation in the context of major depression [37] and in treatment-resistant bipolar depression [38].”
BackgroundTu, J. C., Xiao, B., Yuan, J. P., Lanahan, A. A., Leoffert, K., Li, M., Linden, D. J., & Worley, P. F. (1998) · Neuron · doi:10.1016/s0896-6273(00)80589-9 · Cited by 862 · cited 1×
“Group I mGlu receptors predominantly have a postsynaptic localization around iGlu receptors and are associated with the Homer family of proteins, which functionally link group I mGlu receptors with IP3 receptors, as well as with Shank proteins, which function as a part of the NMDA receptor-associated PSD-95 complex (F…”
BackgroundFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“It was found that the competitive NMDA antagonist at glutamatergic sites (2-amino-7-phosphonoheptanoic acid; AP-7), a channel blocker (dizocilpine; MK-801), a partial agonist at strychnineinsensitive glycine sites (1-aminocyclopropanecarboxyli acid [ACPC]) and the selective antagonist of NR2B receptor subtype (eliprod…”
BackgroundHuettner, J. E., & Bean, B. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1307 · Cited by 751 · cited 1×
“Open channel blockers, termed uncompetitive antagonists, require an open receptor pore to allow access to the binding site to cause subsequent antagonism of receptor activity [23].”
Background
Cited by
Wang, J., Um, P., Dickerman, B. A., & Liu, J. (2018) · Nutrients · doi:10.3390/nu10050584 · Cited by 350
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Amidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Metadata
- Authors
- Szewczyk, B., Pałucha-Poniewiera, A., Poleszak, E., Pilc, A., & Nowak, G.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2011-11-21
- Volume
- 21
- Issue
- 1
- Pages
- 91-102
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2167517090
- Cited by
- 49
- References
- 23
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.